Key Points
- Insmed COO Roger Adsett sold 239,850 shares for approximately $32.0 million at an average price of $133.27, reducing his direct ownership by 70.84% to 98,744 shares.
- Insmed reported a stronger-than-expected quarter, with an adjusted loss of $0.06 per share versus the consensus estimate of $0.67 and revenue of $425.5 million, up 296.1% year over year.
- Analysts maintain a broadly positive outlook, with the stock carrying a consensus “Buy” rating and a $205.52 price target, despite some target reductions including JPMorgan’s cut to $175.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 239,850 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares of the company's stock, valued at $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Roger Adsett also recently made the following trade(s):
- On Wednesday, June 3rd, Roger Adsett sold 2,370 shares of Insmed stock. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90.
Insmed Stock Performance
INSM opened at $132.28 on Thursday. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. The business's 50 day moving average is $106.86 and its 200-day moving average is $128.44. The stock has a market cap of $28.89 billion, a PE ratio of -32.18 and a beta of 0.81. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75.
Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The firm had revenue of $425.49 million for the quarter, compared to analysts' expectations of $395.50 million. During the same period last year, the firm earned ($1.70) EPS. The firm's revenue was up 296.1% compared to the same quarter last year. On average, analysts predict that Insmed, Inc. will post -1.85 earnings per share for the current year.
Institutional Trading of Insmed
Several institutional investors and hedge funds have recently bought and sold shares of INSM. EverSource Wealth Advisors LLC raised its holdings in shares of Insmed by 65.6% during the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 263 shares during the period. First Trust Advisors LP boosted its stake in Insmed by 80.8% in the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company's stock worth $4,770,000 after purchasing an additional 21,176 shares during the period. Baird Financial Group Inc. acquired a new position in Insmed in the 2nd quarter worth approximately $2,589,000. Amundi grew its position in Insmed by 21,194.4% during the 2nd quarter. Amundi now owns 11,499 shares of the biopharmaceutical company's stock worth $1,130,000 after purchasing an additional 11,445 shares in the last quarter. Finally, Natixis purchased a new position in Insmed during the 2nd quarter worth approximately $1,072,000.
Key Insmed News
Here are the key news stories impacting Insmed this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised its EPS forecasts across 2026–2030. Its estimates improved to losses of $0.31 per share for Q3 2026 and $0.49 for Q4, while forecasts increased to $1.62 for FY2027, $3.38 for FY2028 and $10.92 for FY2030. The upgrades suggest stronger expectations for Insmed’s commercial growth and eventual profitability.
- Positive Sentiment: Insmed partnered with a patient group on a bronchiectasis study, potentially strengthening patient engagement and the company’s clinical evidence base in a key disease area. Insmed partners patient group on bronchiectasis study
- Neutral Sentiment: The reported short-interest data showed zero shares and a zero-day days-to-cover ratio, indicating no meaningful short-position signal; however, the figures appear unreliable because the reported change was listed as “NaN.”
- Negative Sentiment: COO Roger Adsett sold 239,850 shares for approximately $32.0 million at an average price of $133.27, reducing his holdings by 70.84%. Although insider sales can reflect personal financial planning, the size of the transaction may raise concerns about insider conviction and add near-term selling pressure. Insider trading filing
- Negative Sentiment: JPMorgan reportedly lowered its expectations for Insmed’s stock price, a potentially bearish development that contrasts with HC Wainwright’s more constructive earnings outlook. Details of the revised target were not provided. JPMorgan lowers expectations for Insmed stock price
Analysts Set New Price Targets
Several equities analysts have recently weighed in on INSM shares. Mizuho set a $192.00 price objective on shares of Insmed in a research report on Tuesday, June 16th. JPMorgan Chase & Co. cut their target price on shares of Insmed from $179.00 to $175.00 and set an "overweight" rating for the company in a research note on Monday. BMO Capital Markets started coverage on shares of Insmed in a report on Monday, July 20th. They set an "outperform" rating and a $192.00 target price for the company. Roth Capital restated a "buy" rating on shares of Insmed in a report on Monday, June 8th. Finally, Royal Bank Of Canada decreased their price target on shares of Insmed from $205.00 to $195.00 and set an "outperform" rating on the stock in a research report on Friday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Insmed currently has a consensus rating of "Buy" and a consensus price target of $205.52.
Read Our Latest Report on Insmed
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
